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Abstract
Background:  Vaccination of macaques with live attenuated simian immunodeficiency virus (SIV) provides
significant protection against the wild-type virus. The use of a live attenuated human immunodeficiency virus (HIV)
as AIDS vaccine in humans is however considered unsafe because of the risk that the attenuated virus may
accumulate genetic changes during persistence and evolve to a pathogenic variant. We earlier presented a
conditionally live HIV-1 variant that replicates exclusively in the presence of doxycycline (dox). Replication of this
vaccine strain can be limited to the time that is needed to provide full protection through transient dox
administration. Since the effectiveness and safety of such a conditionally live virus vaccine should be tested in
macaques, we constructed a similar dox-dependent SIV variant. The Tat-TAR transcription control mechanism in
this virus was inactivated through mutation and functionally replaced by the dox-inducible Tet-On regulatory
system. This SIV-rtTA variant replicated in a dox-dependent manner in T cell lines, but not as efficiently as the
parental SIVmac239 strain. Since macaque studies will likely require an efficiently replicating variant, we set out
to optimize SIV-rtTA through in vitro viral evolution.
Results: Upon long-term culturing of SIV-rtTA, additional nucleotide substitutions were observed in TAR that
affect the structure of this RNA element but that do not restore Tat binding. We demonstrate that the bulge and
loop mutations that we had introduced in the TAR element of SIV-rtTA to inactivate the Tat-TAR mechanism,
shifted the equilibrium between two alternative conformations of TAR. The additional TAR mutations observed
in the evolved variants partially or completely restored this equilibrium, which suggests that the balance between
the two TAR conformations is important for efficient viral replication. Moreover, SIV-rtTA acquired mutations in
the U3 promoter region. We demonstrate that these TAR and U3 changes improve viral replication in T-cell lines
and macaque peripheral blood mononuclear cells (PBMC) but do not affect dox-control.
Conclusion: The dox-dependent SIV-rtTA variant was optimized by viral evolution, yielding variants that can be
used to test the conditionally live virus vaccine approach and as a tool in SIV biology studies and vaccine research.
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Background
More than 20 years after the identification of human
immunodeficiency virus (HIV) as the causative agent of
AIDS, an effective HIV/AIDS vaccine remains elusive. All
vaccine candidates thus far tested in human efficacy trials
have failed to prevent HIV infection or suppress the viral
load. In the experimental model system of pathogenic
simian immunodeficiency virus (SIV) in macaques, live
attenuated virus vaccines have proven to be much more
effective than other AIDS vaccine approaches. For exam-
ple, 95% of the Indian rhesus macaques immunized with
a live attenuated SIV demonstrated a viral load suppres-
sion of more than 3 logs (compared to unvaccinated ani-
mals) upon challenge with a wild-type SIV, whereas such
protection was observed in only 7% of macaques immu-
nized with other vaccine strategies [1]. In most of the stud-
ies, SIV was attenuated through deletion of one or several
accessory functions from the viral genome (reviewed in
[1-4]). Although the majority of macaques vaccinated
with such deletion variants of SIV can efficiently control
replication of pathogenic challenge virus strains, the
attenuated virus could revert to virulence and cause dis-
ease over time in some vaccinated animals [5-8]. Simi-
larly, some of the long-term survivors of the Sydney Blood
Bank Cohort infected with an attenuated HIV-1 variant in
which nef and long terminal repeat (LTR) sequences were
deleted, eventually progressed to AIDS [9]. An HIV-1 Δ3
variant with deletions in the vpr, nef and LTR sequences
regained substantial replication capacity in long-term cell
culture infections by acquiring compensatory changes in
the viral genome [10]. These results underline the evolu-
tionary capacity of attenuated SIV/HIV strains, which
poses a serious safety risk for any future experimentation
with live attenuated HIV vaccines in humans.
Evolution of the attenuated vaccine virus upon vaccina-
tion is due to the persistence of the virus and ongoing low-
level replication. The error-prone viral replication
machinery can facilitate the generation and accumulation
of mutations in the viral genome that improve replication
and pathogenicity. To minimize the prospect of such
undesired evolution of the vaccine strain, we and others
previously presented a unique genetic approach that
exploits a conditionally live HIV-1 variant [11-15]. In our
HIV-rtTA variant, the Tat-TAR regulatory mechanism that
controls viral transcription was inactivated by mutation of
both the Tat protein and the TAR RNA element, and func-
tionally replaced by the components of the Tet-On system
for inducible gene expression [16]. The rtTA gene encod-
ing a synthetic transcriptional activator was inserted in
place of the nef gene, and the corresponding tet-operator
(tetO) DNA binding sites were inserted into the LTR pro-
moter. Since the rtTA protein can only bind tetO and acti-
vate transcription in the presence of doxycycline (dox),
HIV-rtTA replicates exclusively when dox is administered.
Upon vaccination with this virus, replication can be
switched on temporarily and controlled to the extent
needed for induction of the immune system by transient
dox administration. Upon long-term in vitro passage of
the initial HIV-rtTA variant on T cells, the virus acquired
additional modifications in both the rtTA and tetO com-
ponents that significantly improved replication [17-22].
This designer HIV-rtTA was thus optimized through in
vitro virus evolution, resulting in a dox-dependent variant
that replicates in vitro in T cell lines and ex vivo in human
lymphoid tissue [23]. In addition, we constructed an HIV-
1 variant that depends not only on dox for gene expres-
sion, but also on the T20 peptide for cell entry [24].
To evaluate the safety and effectiveness of such a condi-
tionally replicating virus as a candidate AIDS vaccine, a
dox-dependent SIV variant is needed that can be tested in
macaques. Moreover, such an SIV variant may be an ideal
tool to study the immune correlates of vaccine protection,
since both the level and duration of virus replication can
in principle be controlled by dox administration. Such
studies may reveal the critical information needed for the
design of an HIV vaccine that is safe and equally effective
as a live attenuated virus. Based on our experience in
developing HIV-rtTA, we recently constructed a similar
dox-dependent SIVmac239 variant [25]. Surprisingly,
inactivation of the Tat protein was not allowed in the SIV-
rtTA context, even though gene expression was transcrip-
tionally controlled by the incorporated Tet-On system.
This result suggests that Tat has additional essential func-
tions in SIV replication in addition to its role in the acti-
vation of transcription. The Tat-positive SIV-rtTA variant
replicated in a dox-dependent manner in T cell lines, but
not as efficiently as the parental SIVmac239 strain. We
anticipated that SIV-rtTA could evolve to a better replicat-
ing variant and therefore initiated multiple cultures. We
did indeed identify modifications in the U3 and TAR
regions that significantly enhance SIV-rtTA replication in
T cell lines and macaque peripheral blood mononuclear
cells (PBMC). Importantly, these modifications do not
affect dox-control. These evolved SIV-rtTA variants should
allow future in vivo studies in macaques.
Results
In vitro evolution of the dox-inducible SIV-rtTA variant
We recently described the construction of a dox-depend-
ent SIVmac239 variant in which the natural Tat-TAR
mechanism of transcription control was replaced by the
dox-inducible Tet-On gene expression system (Fig. 1A). In
this variant, the bulge and loop sequences in stem-loop 1
(SL1) and stem-loop 2 (SL2) of TAR are mutated (TARm;
substituted nucleotides marked in a gray circle in Fig. 1B),
which prevents the binding of Tat and precludes Tat-
responsiveness of the LTR promoter. Furthermore, this
virus carries the gene encoding the rtTA transcriptionalRetrovirology 2008, 5:44 http://www.retrovirology.com/content/5/1/44
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Evolution of the dox-inducible SIV-rtTA variant Figure 1
Evolution of the dox-inducible SIV-rtTA variant. (A) In the SIVmac239-based SIV-rtTA variant, the Tat-TAR regulatory 
mechanism was inactivated through mutation of TAR (TARm), and functionally replaced by the dox-inducible Tet-On regula-
tory system through the introduction of the gene encoding the rtTA transcriptional activator protein at the site of the nef gene 
and two dox-responsive tet operator (tetO) elements between the NFκB and Sp1 sites in the U3 promoter region [25]. The 
TAR mutations and tetO elements were introduced in both the 5' and 3' LTR. (B) The TAR RNA element of SIV-rtTA can fold 
a branched hairpin structure with three stem-loop domains (SL1-3). The mutations that had been introduced in SL1 and SL2 to 
inactivate TAR, are encircled in gray (SL1: +27U-A, +28U-A, +34C-A, +36G-U; SL2: +62U-A, +68C-A, +70G-U). Upon long-term cul-
turing of SIV-rtTA in PM1 cells, additional nucleotide substitutions are observed in TAR. The number of the culture in which 
the mutation is observed is shown (#), with the asterisk (*) indicating the transient presence of the mutation. (C) Alternative 
folding of the SL1 domain can result in a 6-bp spacer between the bulge and loop sequences. However, this spacer extension 
slightly reduces TAR stability (ΔG5 bp = -67.5 kcal/mole; ΔG6 bp = -67.2 kcal/mole). Alternative folding of the +63A-G mutated 
TAR RNA results in a 6-bp bulge-loop spacer in SL2 but does not affect TAR stability (ΔG5 bp = ΔG6 bp = -67.5 kcal/mole). For-
mation of an A+63-U+78 base pair in the +78C-U mutant results in a similar 6-bp bulge-loop spacer in SL2 and increases the stabil-
ity of this TAR variant (ΔG5 bp = -65.2 kcal/mole; ΔG6 bp = -65.8 kcal/mole). (D) TAR can fold an alternative extended hairpin 
structure in which the SL1 and SL2 sequences fold a large stem-loop structure. The introduced and acquired mutations are 
shown as in B.
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activator protein at the position of the nef gene and two
dox-responsive tet operator (tetO) elements between the
NFκB and Sp1 binding sites in the U3 promoter region
(Fig. 1A). Dox induces a conformational change in the
rtTA protein that triggers binding to the tetO sites and acti-
vation of transcription from the downstream start site. In
the absence of dox, rtTA cannot bind to the tetO sites and
viral gene expression is not activated. Since transcription
is critically dependent on dox, this SIV-rtTA variant repli-
cates exclusively in the presence of dox. As the TAR muta-
tions and tetO elements were introduced in both the 5'
and 3' LTR, they are stably maintained in the viral prog-
eny.
We demonstrated that SIV-rtTA replicates in a dox-
dependent manner in PM1 T-cells, but not as efficiently as
the wild-type SIVmac239 variant [25]. Since macaque
studies will likely require an efficiently replicating variant,
we set out to optimize SIV-rtTA through in vitro viral evo-
lution. We therefore started 13 cultures of the Tat-positive
SIV-rtTA variant in PM1 cells and passaged the virus onto
fresh cells at the peak of infection when massive syncytia
were observed. The cultures were maintained for up to
234 days. The period between infection and the appear-
ance of syncytia decreased over time and we could reduce
the volume of the virus inoculum that is needed to start a
new infection. These observations indicate that the repli-
cation capacity of the virus had improved and we ana-
lyzed the proviral genome present in these long-term
cultures. This analysis revealed that the virus stably main-
tained the introduced TAR mutations, rtTA gene and tetO
elements, but acquired additional mutations in the LTR
region (Fig. 2). We observed one or several nucleotide
substitutions in the TAR sequence in all 13 cultures. In
eight of these cultures, additional nucleotide substitutions
or deletions were present in the Sp1 sites, which are
located between the tetO sites and the TATA box.
Mutations in TAR affect RNA structure
We observed an A-to-G substitution at TAR position +63
in seven independent cultures (Fig. 1B). The high fre-
quency may indicate that this change is an important evo-
lutionary route toward improved replication. This
substitution may induce a base pairing rearrangement in
SL2 by formation of a G+63-C+78 base pair, resulting in a 6-
bp spacer between the bulge and loop domains (Fig. 1C).
Remarkably, we observed a C-to-U substitution at posi-
tion +78 in two other cultures that has the same impact on
the TAR structure, as it also allows the formation of a 6-bp
bulge-loop spacer through A+63-U+78 base pairing in SL2
(Fig. 1C). In fact, the mutated SL1 can also form a 6-bp
spacer between the bulge and loop domains (Fig. 1C),
although analysis of the thermodynamic stability with the
MFold RNA folding software [26,27] revealed that this
spacer extension slightly reduces TAR stability (ΔG5 bp = -
67.5 kcal/mole; ΔG6 bp = -67.2 kcal/mole). Another
remarkable mutation is seen at position +21 in three cul-
tures. This G-to-A mutation destabilizes the lower stem of
SL1 by generating an A+21-C+49 mismatch but it creates a 7-
nt sequence (CUAGCAG) at the start of the SL1 sequence
that is repeated at the start of SL2. Nearly all other nucle-
otide substitutions were observed in individual cultures.
These mutations seem to destabilize the TAR structure by
either replacing a G-C base pair by a less stable G-U base
pair, or by causing a base pair mismatch (Fig. 1B).
Recently, Pachulska-Wieczorek et al. showed that HIV-2
TAR can fold an alternative secondary structure in addi-
tion to the classical branched hairpin (BH) structure with
SL1, SL2 and SL3 [28]. In this extended hairpin (EH)
structure, the SL1 and SL2 sequences fold a single,
extended stem-loop structure. SIVmac239 TAR, which is
very similar to HIV-2 TAR, and the mutated SIV-rtTA TAR
may also co-exist in comparable BH and EH forms (Fig.
1B and 1D, respectively). At first glance, the individual
TAR mutations observed in SIV-rtTA upon prolonged cul-
turing seem to either stabilize the EH structure by creating
more stable base pairs (e.g. replacement of a G-U base pair
by a more stable A-U base pair) or destabilize this struc-
ture by creating mismatches or less stable base pairs (e.g.
replacement of a G-C base pair by a G-U base pair). Since
the equilibrium between the BH and EH conformers may
be essential in viral replication, we used MFold RNA anal-
ysis to estimate the thermodynamic stability of the BH
and EH structures for the wild-type (TARwt in SIVmac239),
mutated (TARm in SIV-rtTA) and evolved TAR sequences
(Table 1). The difference between these ΔG values
(ΔΔGBH-EH) reflects whether the BH form is more stable
and favored (ΔΔGBH-EH < 0) or the EH form (ΔΔGBH-EH >
0). This analysis revealed that TARwt is more stable in the
EH form (ΔG = -68.2 kcal/mole) than in the BH form (ΔG
= -65.3), yielding a ΔΔGBH-EH of 2.9 kcal/mole. The bulge
and loop mutations that we introduced in TARm to pre-
vent Tat trans-activation stabilize the BH form and desta-
bilize the EH structure. As a result the ΔΔGBH-EH is reduced
to -3.6 kcal/mole. The most frequent +63A-G substitution
does not affect the stability of the BH structure but par-
tially restores the stability of the EH form, resulting in a
ΔΔGBH-EH of -1.2 kcal/mole. Most of the other nucleotide
substitutions reduce the stability of the BH structure and
at the same time stabilize the EH structure. As a result, the
ΔΔGBH-EH of these TAR elements is increased to values
between -2.0 to 6.3 kcal/mole. In cultures 4, 9 and 10, the
virus accumulated multiple TAR mutations that resulted
in a gradual increase in the ΔΔGBH-EH. In cultures 1 and 5,
such a gradual increase through the accumulating muta-
tions is not observed, but the virus acquired additional
mutations in the Sp1 region. These results suggest that the
bulge and loop mutations that we introduced in SIV-rtTA
shifted the BH-EH equilibrium into the direction of theRetrovirology 2008, 5:44 http://www.retrovirology.com/content/5/1/44
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SIV-rtTA acquires additional mutations in the U3 and TAR region upon long-term culturing Figure 2
SIV-rtTA acquires additional mutations in the U3 and TAR region upon long-term culturing. SIV-rtTA was cul-
tured with dox in PM1 cells for up to 234 days. Cellular proviral DNA was isolated from 13 independent cultures at different 
times and the LTR region was subsequently PCR amplified and sequenced. The number of the culture (#) and the day of sam-
pling are indicated on the left. The -90 to +130 U3/R region is shown with +1 indicating the transcription initiation site. The 
Sp1 and TATA box are shown in grey. The mutations that were introduced in TAR to abolish Tat-responsiveness are under-
lined. The additional nucleotide substitutions and deletions (Δ) observed in the SIV-rtTA cultures are indicated.
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 # day GGGGATGTTACGGGGAGGTACTGGGGAGGAGCCGGTCGGGAACGCCCACTTTCTTGATGTATAAATATCACTGCATTTCGCTCTGTATTCAGTCGCTCTGCGGAGAGGCT 
 1  72 -------------------------------------------------------------------------------------------------------------- 
   104 ---------------------------∆∆∆∆∆∆∆∆∆∆∆∆∆∆--------------------------------------------------------------------- 
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BH form, and that nucleotide substitutions selected dur-
ing virus evolution reduce this preference for the BH form
or even restore the preference for the EH structure. The
only exceptions are the +46C-T  and +72G-A  mutations
observed in culture 12, which only marginally affect the
BH and EH stability. The virus in this culture did however
acquire an additional nucleotide substitution in the Sp1
sites, which may have improved replication.
To demonstrate that the introduced and acquired muta-
tions do indeed affect TAR folding, we analyzed the elec-
trophoretic mobility of in vitro transcribed RNAs
corresponding to TARwt, TARm and the evolved +21G-A,
+63A-G and +78C-U variants. The RNAs were denatured by
heat, renatured in the presence of MgCl2 and subsequently
analyzed by denaturing and non-denaturing polyacryla-
mide gel electrophoresis. All RNAs migrate similarly on a
denaturing polyacrylamide gel, as expected based on their
identical size (Fig. 3A). In contrast, TARm migrates slower
than TARwt on the non-denaturing gel (Fig. 3B). Since
branched RNA conformers migrate slower than extended
molecules, the observed migration pattern is in agreement
with a predominant EH structure of TARwt under these
conditions, as previously shown by Pachulska-Wieczorek
et al. [28], and a BH structure of TARm. The +21G-A, +63A-
G and +78C-U TAR RNAs show the fast wild-type migration
capacity, which demonstrates that these mutations restore
EH folding of TAR in this in vitro assay.
SIV-rtTA expresses the wild-type Tat protein but the muta-
tions introduced in TAR prevent binding of Tat and activa-
tion of transcription [25]. One possibility is that the
acquired TAR mutations restore Tat binding. We therefore
performed an Electrophoretic Mobility Shift Assay
(EMSA) to analyze the effect of the +21G-A, +63A-G and
+78C-U changes on Tat binding. In the absence of Tat, all
in vitro transcribed TAR RNAs migrate similarly on the
EMSA gel (Fig. 3C). Upon incubation with Tat, TARwt effi-
ciently shifts into a slower migrating Tat-TAR complex.
This Tat-TAR complex is not observed for TARm, demon-
strating that the introduced TAR mutations do effectively
prevent Tat binding. The +21G-A, +63A-G and +78C-U substi-
tutions do not restore Tat binding.
Mutations in U3 and TAR do not affect promoter activity
In addition to the mutations in TAR, SIV-rtTA acquired
mutations in the U3 region upon long-term culturing
(Fig. 2). We observed a G-to-A substitution in one of the
four G-rich Sp1 sites in six cultures. Furthermore, a 1-nt
deletion in one of the Sp1 sites and a 14-nt deletion that
affects two Sp1 sites were observed once. Since the U3 and
TAR mutations may affect SIV-rtTA promoter activity, we
re-cloned the evolved LTR sequences into an LTR pro-
moter-luciferase reporter construct. We made constructs
with the +21G-A, +63A-G or +78C-U TAR mutation. The +63A-
G mutation was also combined with the G-to-A substitu-
tion (mSp1) or 14-nt deletion in the Sp1 sites (ΔSp1),
exactly as it appeared at day 115 in culture 3 and at day
104 in culture 1, respectively.
To test the dox responsiveness of these SIV-rtTA promot-
ers, these plasmids were co-transfected with an rtTA-
expressing plasmid into C33A cervix carcinoma cells. After
two days of culturing with 0 to 1000 ng/ml dox, we meas-
ured the intracellular luciferase level, which reflects gene
expression (Fig. 4A). The original SIV-rtTA promoter was
inactive in the absence of dox and its activity gradually
increased with an increasing dox level. All evolved pro-
moter variants showed a similar low activity without dox
and a similarly high activity with dox, which demon-
strates that the acquired U3 and TAR mutations do not sig-
Table 1: Nucleotide substitutions affect the stability of the branched hairpin (BH) and extended hairpin (EH) conformation of TAR.
ΔGBH
a ΔGEH
a ΔΔGBH-EH
b culturec
TARwt (SIVmac239) -65.3 -68.2 2.9
TARm (SIV-rtTA) -67.5 -63.9 -3.6
+63A-G -67.5 -66.3 -1.2 172, 281, 3115, 481, 6124, 7136, 1328
+63A-G +44C-T -65.9 -63.9 -2.0 1153
+63A-G +21G-A -62.5 -66.6 4.1 4234
+78C-T -65.8 -65.7 -0.1 532, 1037
+78C-T +47T-C -63.7 -64.1 0.4 5198
+21G-A -62.5 -64.2 1.7 948
+21G-A +78C-T +99C-T -58.4 -63.6 5.2 5124
+21G-A +74G-A -58.8 -63.4 4.6 9130
+5G-A +59A-T -63.3 -69.6 6.3 10136
+73T-C -66.5 -65.1 -1.4 11147
+73T-C +49C-T -64.2 -64.9 0.7 8222
+46C-T +72G-A -67.6 -63.6 -4.0 12120
a ΔG values (kcal/mole) as determined with the Mfold RNA analysis software. b ΔΔGBH-EH = ΔGBH-ΔGEH. c Culture in which the mutation is observed 
(see Figure 2), with the day of earliest detection in superscript.Retrovirology 2008, 5:44 http://www.retrovirology.com/content/5/1/44
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Acquired mutations in TAR restore secondary structure but  not Tat binding Figure 3
Acquired mutations in TAR restore secondary struc-
ture but not Tat binding. In vitro transcribed TAR RNA 
corresponding to the wild-type SIVmac239 (TARwt), SIV-
rtTA (TARm) and the evolved +21G-A, +63A-G and +78C-U var-
iants was denatured by heat, renatured in the presence of 
MgCl2 and analyzed on a denaturing gel (A) and on a non-
denaturing gel (B). Under these non-denaturing conditions, 
branched hairpin (BH) RNA conformers migrate slower than 
extended hairpin (EH) molecules [28]. (C) Binding of SIV Tat 
to TAR was analyzed in an Electrophoretic Mobility Shift 
Assay (EMSA). TAR RNA was incubated with 0 or 100 ng Tat 
protein (indicated with - and +, respectively) and analyzed on 
a non-denaturing gel. The position of unbound TAR RNA 
and TAR-Tat complex is indicated.
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U3 and TAR mutations do not affect dox and Tat responsive- ness of the SIV-rtTA promoter Figure 4
U3 and TAR mutations do not affect dox and Tat 
responsiveness of the SIV-rtTA promoter. (A) To 
assay dox responsiveness, C33A cells were transfected with 
LTR-promoter/luciferase reporter constructs corresponding 
to the original and evolved SIV-rtTA variants and an rtTA-
expressing plasmid. After two days of culturing with 0 to 
1000 ng/ml dox, the intracellular luciferase level, which 
reflects promoter activity, was measured. The error bar rep-
resents the standard deviation (SD) for 3 to 8 experiments 
(B) To assay Tat responsiveness, C33A cells were trans-
fected with the promoter/luciferase plasmids and 0 to 50 ng 
SIV Tat-expressing plasmid. Two days after transfection, the 
promoter activity was analyzed by measuring the intracellular 
luciferase activity. The error bar represents the SD for 2 to 4 
experiments. (C) 293T cells were transfected with the SIV-
rtTA proviral constructs and cultured for two days with or 
without dox. Virus production was quantified by measuring 
the CA-p27 level in the culture supernatant. The error bar 
represents the standard deviation for 2 experiments.
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nificantly affect the basal and dox-induced promoter
activity.
To test the Tat responsiveness of the new SIV-rtTA promot-
ers, we transfected C33A cells with the promoter/luci-
ferase plasmids plus 0 to 50 ng SIV Tat-expressing plasmid
[25] and measured the luciferase level after two days (Fig.
4B). Neither the original SIV-rtTA construct nor the
evolved variants responded to Tat. Only the control con-
struct with a wild-type SIVmac239 TAR sequence showed
increased activity with an increasing amount of Tat. Thus,
the acquired U3 and TAR mutations do also not restore
Tat responsiveness, which is in agreement with the inabil-
ity of the evolved TAR RNAs to bind Tat (Fig. 3C).
Evolved U3 and TAR sequences improve SIV-rtTA 
replication
To determine the effect of the acquired U3 and TAR muta-
tions on virus production and replication, we introduced
the evolved LTR sequences into the SIV-rtTA genome. The
mutations were introduced in both the 5' and 3' LTR of
the SIV-rtTA plasmid, such that they are stably inherited in
the viral progeny. The SIV-rtTA constructs were transfected
into 293T cells and after two days of culturing with or
without dox, virus production was quantified by measur-
ing the CA-p27 level in the culture supernatant (Fig. 4C).
The original and new SIV-rtTA variants showed a similarly
high level of virus production with dox and a similarly
low level without dox. These results demonstrate that the
acquired U3 and TAR mutations do not significantly affect
dox-dependent viral gene expression and virus produc-
tion, which is in agreement with the results of the pro-
moter activity assays (Fig. 4A).
To evaluate the replication capacity of the SIV-rtTA vari-
ants, PM1 T-cells were transfected with 5 μg of the proviral
plasmids and cultured in the presence and absence of dox
(Fig. 5A). None of the SIV-rtTA variants replicate in the
absence of dox, which is in agreement with their dox-
dependent promoter activity. In the presence of dox, the
new variants with either the +21G-A, +63A-G or +78C-U TAR
mutation replicate more efficiently than the original SIV-
rtTA, which demonstrates that these TAR mutations signif-
icantly improve viral replication. The +63A-G mSp1 and
+63A-G ΔSp1 variants seem to replicate with a similar effi-
ciency as the +63A-G variant. However, comparison of the
replication capacity of these variants upon transfection of
1  μg of the proviral plasmids revealed that the Sp1-
mutated variants replicate more efficiently (Fig. 5B). This
result demonstrates that the acquired Sp1 mutations fur-
ther improve SIV-rtTA replication. The original SIV-rtTA
did not show any replication within the time frame of this
experiment, which illustrates that the replication capacity
of the new variants has increased significantly. Despite
this large improvement, the new SIV-rtTA variants did not
U3 and TAR mutations improve SIV-rtTA replication Figure 5
U3 and TAR mutations improve SIV-rtTA replica-
tion. (A) PM1 T-cells were transfected with 5 μg of the orig-
inal (grey symbols) or LTR-mutated SIV-rtTA proviral 
plasmid (black symbols) and cultured with or without dox 
(closed and open symbols, respectively). Virus replication 
was monitored by measuring the reverse transcriptase level 
in the culture supernatant. (B) Cells were transfected with 1 
μg SIV-rtTA or SIVmac239 proviral plasmid and cultured 
with dox (SIV-rtTA variants) or without dox (SIVmac239).
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replicate as efficiently as wild-type SIVmac239, which was
included in this experiment for comparison.
To demonstrate that the acquired mutations do not selec-
tively improve viral replication in the human PM1 T cells
that were used in the evolution study, we next assessed the
replication capacity of the SIV-rtTA variants in primary
PBMC isolated from cynomolgus macaques (Fig. 6A). For
comparison, we included the wild-type SIVmac239 and
the SIV-rtTA-mTat variant in which Tat is inactivated by a
Tyr-55-Ala mutation [25]. Upon infection, cells were cul-
tured with or without dox. In the absence of dox, none of
the SIV-rtTA variants showed any replication, while
SIVmac239 replicates efficiently (not shown). SIV-rtTA-
mTat does also not show any replication in the presence
of dox, which is in agreement with previous observations
in T cell lines and indicates that SIV-rtTA requires Tat for a
non-transcriptional function in the viral life cycle. The
original Tat-positive SIV-rtTA replicates poorly in the
PBMC upon dox administration, whereas the new vari-
ants in which we introduced the U3 and TAR changes rep-
licate much more efficiently. However, these viruses do
not replicate as efficiently as wild-type SIVmac239. Simi-
lar results were obtained when replication of the +63A-G,
+63A-G  mSp1 and +63A-G  ΔSp1 variants was tested in
PBMC isolated from rhesus macaques (Fig. 6B). Also in
these cells, the new SIV-rtTA variants replicated to much
higher levels in the presence of dox than in its absence,
although with somewhat delayed replication kinetics
when compared to SIVmac239. These studies suggest that
the evolved LTR sequences significantly improve SIV-rtTA
replication in macaque PBMC. Importantly, the Sp1 and
TAR mutations do not affect dox-control in these primary
cells.
Discussion
In this paper, the optimization of the conditionally live
SIV-rtTA variant through viral evolution is described. We
recently constructed this dox-dependent SIVmac239 vari-
ant by replacing the natural Tat-TAR mechanism of tran-
scription control by the dox-inducible Tet-On regulatory
mechanism. Although the original SIV-rtTA variant repli-
cates in T cell lines and in primary macaque PBMC, it rep-
licates poorly when compared with the parental
SIVmac239 [25](Figs. 5 and 6). Upon long-term cultur-
ing, the virus acquired several mutations in the TAR and
U3 region. These mutations significantly improve viral
replication, but do not affect dox control. We thus gener-
ated novel SIV-rtTA variants that replicate efficiently and
in a dox-dependent manner in both T-cell lines and pri-
mary macaque PBMC.
We previously used virus evolution to optimize a similarly
constructed dox-dependent HIV-1 variant. Upon long-
term culturing, this HIV-rtTA variant acquired several
mutations in the rtTA and tetO components of the intro-
duced Tet-On system, which considerably improved viral
replication [17-19,21]. These optimized rtTA and tetO
components were used for the construction of SIV-rtTA
and these elements were stably maintained upon evolu-
tion of this virus. Unlike HIV-rtTA, SIV-rtTA further
Novel SIV-rtTA variants replicate efficiently in primary  macaque PBMC Figure 6
Novel SIV-rtTA variants replicate efficiently in pri-
mary macaque PBMC. (A) PBMC isolated from cynomol-
gus macaques were infected with the original or LTR-
mutated SIV-rtTA variants. For comparison, cells were 
infected with SIVmac239. Furthermore, we included the SIV-
rtTA-mTat variant in which Tat had been mutated [25]. Cells 
were infected with an equal amount of virus (corresponding 
to 10 ng CA-p27) for 16 h, washed and cultured with dox. 
Replication was monitored by measuring the reverse tran-
scriptase level in the culture supernatant (B) PBMC isolated 
from rhesus macaques were infected with the indicated SIV-
rtTA variants and SIVmac239, using comparable infectious 
titers (based on titration in TZM-bl cells). Cells were inocu-
lated in the presence of dox and the cultures were split 
seven days later with half of the cells continuing to receive 
dox (closed symbols) and the other half receiving no further 
dox treatment (open symbols). Fresh, uninfected anti-CD3 
stimulated cells from allogeneic macaque donors were added 
every two weeks. Replication was monitored by measuring 
the viral RNA copy number in the culture supernatant.
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improved its replication capacity through additional
mutations in the TAR and Sp1 region.
For the construction of SIV-rtTA, both the bulge and loop
domains in TAR were mutated to prevent binding of Tat
and trans-activation of transcription. Interestingly, the
acquired nucleotide substitutions in TAR upon SIV-rtTA
evolution do not restore the wild-type bulge and loop
sequences. The frequently observed changes at positions
+63 and +78 do however allow the formation of a 6-bp
spacer between the bulge and loop domains in SL2 (Fig.
1C). This is remarkable since trans-activation by HIV-2
Tat, which is very similar to SIV Tat, is optimal with a
bulge-loop spacing of 6 bp [29]. However, we demon-
strate that the evolved TAR elements do not bind Tat and
that transcription from the modified SIV-rtTA promoter is
not activated by Tat. We also frequently observed a G-to-
A nucleotide substitution at position +21, which creates a
7-nt repeat at the start of SL1 and SL2. If this sequence
would bind a transcription factor, either as LTR DNA or
TAR RNA, duplication of the motif could increase pro-
moter activity. However, the +21 substitution did not
affect the low basal promoter activity in the absence of
dox or the high induced activity in the presence of dox.
Similarly, the other TAR and U3 mutations do not affect
the transcription process.
In silico RNA folding analysis and in vitro RNA mobility
assays revealed that the acquired TAR mutations do affect
the structure of this RNA element. As previously proposed
for HIV-2 TAR [28], the TAR motif of SIVmac239 and SIV-
rtTA may fold alternative structures: the classical branched
hairpin (BH) structure with SL1, SL2 and SL3 (Fig. 1B)
and an extended hairpin (EH) structure in which the SL1
and SL2 sequences form a single, extended stem-loop
structure (Fig. 1D). We demonstrate that the wild-type
TAR in SIVmac239 favors the EH form. The bulge and
loop mutations that we had introduced in SIV-rtTA shift
the equilibrium toward the BH form. Interestingly, nearly
all mutations observed in the evolved variants partially or
completely restored the wild type situation in which the
EH form is favored. Although the role of the EH TAR con-
formation and the possible EH-BH riboswitch in the SIV
life cycle has yet to be resolved, these results suggest that a
proper EH-BH equilibrium is important for efficient viral
replication.
Interestingly, alternative folding of the leader RNA has
also been proposed for HIV-1. In this case however, the
TAR structure is identical in the alternative conformations.
The energetically favored structure of the HIV-1 leader is
formed by a long-distance interaction (LDI) between the
sequences around the polyadenylation site and the dimer-
ization initiation signal (DIS) [30]. In the alternative
structure, termed the branched multiple hairpin (BMH)
conformation, both the polyadenylation and DIS motifs
fold a stem-loop element. Mutations that affect the equi-
librium between the dimerization-incompetent LDI struc-
ture and the dimerization-prone BMH structure
significantly affect HIV-1 replication [30-33]. Our recent
studies with HIV-rtTA showed that HIV-1 TAR can be trun-
cated, deleted or replaced by a non-related stem-loop ele-
ment when not required for the activation of
transcription, which demonstrates that TAR has no addi-
tional essential role in HIV-1 replication [34]. However,
destabilization of TAR blocked replication, which can
possibly be explained by unwanted pairing of free nucle-
otides in the destabilized TAR structure with downstream
leader sequences, thereby affecting the LDI-BMH equilib-
rium [35]. Thus, although TAR is not a functional domain
of the LDI-BMH conformational switch in HIV-1, it can
indirectly affect this function. In analogy with these HIV-
1 studies, it cannot be excluded that the bulge and loop
mutations introduced in SIV-rtTA caused misfolding of
the leader RNA. These mutations may change the local
TAR folding or generate a new sequence with complemen-
tarity to downstream sequences, which could result in an
interaction between TAR and other leader domains. The
additional TAR mutations in the evolved variants may
prevent this interaction and thus restore viral replication.
Although further analyses will be needed to understand
this misfolding scenario, it is supported by our recent
observation that precise truncation of structural TAR
domains is compatible with SIV-rtTA replication (manu-
script in preparation).
We demonstrated that SIV-rtTA requires wild-type Tat pro-
tein for replication in T-cell lines [25] and primary
macaque PBMC (this study), although gene expression is
controlled by the incorporated Tet-On system. These
results suggest that Tat has additional functions in the SIV
replication cycle in addition to its role in the activation of
transcription. For this reason, the SIV-rtTA variant used in
this study encodes the wild-type Tat protein. Reversion of
the bulge and loop mutations in TAR, which had been
introduced to prevent Tat binding and trans-activation of
transcription, would restore the Tat-TAR mechanism of
transcription control. However, this evolution route
would require multiple nucleotide substitutions, which is
not likely to occur. Indeed, we never observed restoration
of the Tat-TAR axis in numerous long-term cultures of SIV-
rtTA. Nevertheless, the likelihood of this unwanted evolu-
tion route can be further reduced by introducing novel
mutations in Tat that would inactivate the first function
(activation of transcription) but not the second function
(currently unknown). However, such Tat mutations
remain to be identified. Alternatively, this evolution route
can be blocked by the complete or partial deletion of TAR
(e.g. only SL1 and SL2), as we recently showed that theRetrovirology 2008, 5:44 http://www.retrovirology.com/content/5/1/44
Page 11 of 14
(page number not for citation purposes)
complete removal of TAR in HIV-rtTA does not signifi-
cantly affect replication [34].
The optimization of SIV-rtTA through viral evolution
resulted in new dox-controlled variants that replicate effi-
ciently in the PM1 T cell line and in primary PBMC from
cynomolgus and rhesus macaques. These novel SIV-rtTA
variants may be good candidates to study the efficacy and
safety of a conditionally live virus as AIDS vaccine in
macaques. Furthermore, this virus may be an ideal tool to
study the immune correlates of protection if the level and
duration of replication in vivo can be stringently control-
led by dox administration. Such studies may reveal crucial
information needed for the design of a safe and effective
HIV vaccine.
Methods
Viruses and cells
We previously described the construction of the SIV-rtTA
plasmid encoding the dox-dependent virus that is based
on the SIVmac239 isolate [36](GenBank accession
number M33262) and contains the wild-type Tat gene
(pSIV-rtTA-Tatwt  in [25]). The plasmid pSIVmac239
encodes the full-length SIVmac239 isolate [37].
Human embryonal kidney (HEK) 293T and cervical carci-
noma C33A cells [38] were cultured in 2-cm2 wells and
transfected with 1 μg SIV-rtTA or SIVmac239 DNA by cal-
cium phosphate precipitation, as previously described
[19]. PM1 T cells [39] were cultured and transfected by
electroporation [25]. PBMC were isolated from cynomol-
gus [40] and rhesus macaques [41] and cultured as
described for the PM1 cells [25]. Cells were activated with
2 μg/ml PHA (cynomolgus macaques PBMC) or anti-CD3
monoclonal antibody (rhesus macaques PBMC) for two
days prior to infection with C33A or 293T produced virus,
and maintained with 100 units/ml recombinant IL-2 fol-
lowing infection. Cells were cultured with 1000 ng/ml
dox (Sigma D-9891) when indicated. The virus level in the
culture medium was determined by CA-p27 ELISA (SIV
core antigen kit, Beckman Coulter), by quantification of
the viral RNA copy number in the culture supernatant
[42], or with a real-time PCR-based reverse transcriptase
(RT) assay [43] in which AMV RT was used as standard.
Proviral DNA analysis and cloning of evolved sequences
Virus infected cells were pelleted by centrifugation at
1,500 g for 4 min and washed with phosphate-buffered
saline. DNA was solubilized by resuspending the cells in
10 mM Tris-HCl pH 8.0, 0.1 mM EDTA, 0.5% Tween 20,
followed by incubation with 200 μg of proteinase K per
ml at 56°C for 30 min and at 95°C for 10 min. Proviral
DNA sequences were PCR amplified from total cellular
DNA and the purified PCR product was subsequently
sequenced with nested primers. For the analysis of the 3'-
half of rtTA and the 3' LTR, we used primers tTA3 (CTGT-
GTCAGCAAGGCTTCTC, nucleotides 9681–9700 in pSIV-
rtTA-Tatwt) and SIV-LTR3 (ATCGGTACCGACGTCTC-
GAGTGCTAGGGATTTTCCTGCTTCG, nt 10991–10959)
for the amplification, and tTA4 (ACGCACTGTACGCTCT-
GTC, nt 9709–9727), SIV-LTR8 (AAAGGGTCCTAACA-
GACCA, nt 10944–10926) and SIV-LTR10
(GAAGAGGGCTTTAAGCAAGCA, nt 10832–10812) for
sequencing. For the analysis of Tat-coding exon 1, we used
SIV-Tat2 (GGGAACCATGGGATGAATG, nt 6255–6273)
and SIV-Env4 (CCCTGTCATGTTGAATTTACAGCT, nt
7192–7169) for amplification and SIV-Tat1 (GGTAGT-
GGAGGTTCTGGAAGA, nt 6274–6294) for sequencing.
For the analysis of Tat-coding exon 2 and the 5'-half of
rtTA, we used primers SIV-LTR1 (AGTACTGCGGCCG-
CAGGCATGCTGGGATGTGTTTGGCAATTG, nt 8691–
8712) and tTA-Rev3 (TGAAATCGAGTTTCTCCAGGCCA-
CATATGA, nt 9921–9901) for amplification, and SIV-
Env5 (GGTTTGACCTTGCTTCTTGGAT, nt 8712–8733)
and tTA-Rev4 (GGAAGGCAGGTTCGGCTC, nt 9882–
9865) for sequencing.
For the cloning of the evolved U3 and TAR sequences into
the 5' LTR of SIV-rtTA, the proviral DNA was PCR ampli-
fied with primers SIV-LTR4 (AGCTCTAGAGCGGCCGCT-
GGAAGGGATTTATTACAGTGCA, nt 1–36) and SIV-LTR5
(ATGGACGTCTCGAGTCGCATGCTAGGCGCCAATCT-
GCTAGGGATTTTCCTGCT, nt 896–867). The PCR prod-
uct was ligated into the pCR2.1-TOPO TA-cloning vector
(Invitrogen). The NotI-NarI fragment of the TA-clone was
subsequently used to replace the corresponding 5'-LTR
fragment in SIV-rtTA. For the introduction of the U3 and
TAR mutations into the 3' LTR, we amplified the proviral
DNA with primers tTA3 and SIV-LTR3. The PCR product
was digested with EcoRI (position 10584) and XhoI (posi-
tion 10981), and used to replace the corresponding 3'-LTR
fragment in pBS-3'SIV-rtTA [25]. The NheI-XhoI fragment
(nt 8809–10981) of these 3'-LTR modified plasmids was
subsequently used to replace the corresponding fragment
in the 5'-LTR modified SIV-rtTA plasmids, which resulted
in SIV-rtTA constructs with the modified U3 and TAR
sequences in both LTRs.
For the introduction of the evolved U3 and TAR sequences
into the SIV-rtTA LTR-promoter/luciferasefirefly-reporter
construct, the EcoRI-XhoI digested tTA3/SIV-LTR3 PCR
product (as described for the construction of pBS-3'SIV-
rtTA variants) was used to replace the corresponding LTR
fragment in the SIV-rtTA LTR-luciferasefirefly plasmid [25].
We used standard molecular biology procedures for all
manipulations and plasmids were propagated in either E.
coli  TOP10 (for TA-cloning; Invitrogen), DH5α (pBS-
3'SIV-rtTA and LTR-luc plasmids) or Stbl4 (pSIV-rtTA-Retrovirology 2008, 5:44 http://www.retrovirology.com/content/5/1/44
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Tatwt constructs; Invitrogen). All constructs were verified
by sequence analysis.
Promoter activity assay
To determine dox-responsiveness of the promoter-luci-
ferase constructs, C33A cells were transfected with 20 ng
LTR-luciferasefirefly plasmid, 0.4 ng rtTA-expressing plas-
mid pCMV-rtTAF86Y A209T [19], 0.5 ng pRL-CMV
(Promega) and 980 ng pBluescript. This pBluescript was
added as carrier DNA, and pRL-CMV, in which the expres-
sion of renilla luciferase is controlled by the CMV imme-
diate early enhancer/promoter, was co-transfected to
allow correction for differences in transfection efficiency.
The cells were cultured after transfection for 48 hours with
0–1000 ng/ml dox. Cells were lysed in Passive Lysis Buffer
and firefly and renilla luciferase activities were deter-
mined with the Dual-Luciferase assay (Promega). The
expression of firefly and renilla luciferase was within the
linear range and no squelching effects were observed. The
promoter activity was calculated as the ratio of the firefly
and renilla luciferase activities, and corrected for between
session variation [44]. To determine Tat-responsiveness of
the promoter-luciferase constructs, C33A cells were trans-
fected with 20 ng LTR-luciferasefirefly plasmid, plus 0–50
ng SIVmac239 Tat-expressing plasmid pcDNA3-SIV-Tatwt
[25], 0–50 ng pcDNA3 (empty expression vector, total
amount of Tat-expressing plasmid and pcDNA3 was kept
at 50 ng), 0.5 ng pRL-CMV and 950 ng pBluescript. Cells
were cultured for 48 hours and luciferase activities were
subsequently measured.
Tat binding and TAR conformer assay
32P-labeled TAR transcripts were produced as described
previously [25]. In brief, the TAR region in SIV-rtTA LTR-
luciferase plasmids was amplified by PCR with a 5' primer
encoding the T7 promoter sequence directly upstream of
the +1 position. The DNA products were in vitro tran-
scribed with the MEGAshortscript T7 transcription kit
(Ambion). The TAR RNA transcripts were dephosphor-
ylated with calf intestine alkaline phosphatase and 5'-end
labeled with the KinaseMax kit (Ambion) in the presence
of 1 μl [γ-32P]-ATP. The labeled transcripts were purified
on a denaturating 8% acrylamide gel.
For the Tat binding assay, 32P-labeled TAR RNA (200
counts/s) was denatured in 10 μl water for 1 min at 85°C
followed by snap cooling on ice. After addition of 10 μl
200 mM KCl, 100 mM Tris-HCl (pH 8.0), the RNA was
renaturated at room temperature for 15 min. Binding of
HIS-tagged SIVmac-J5 Tat protein (obtained from the
Centralised Facility for AIDS reagents at the National
Institute for Biological Standards and Control, Potters Bar,
UK; ARP685) was analyzed by electrophoretic mobility
shift assay (EMSA) as described [25]. In brief, TAR RNA
(200 counts/s) was incubated with 0 or 100 ng Tat protein
and 1 μg calf liver tRNA (Roche) as competitor in 50 mM
Tris-HCl (pH 8.0), 20 mM KCl, 5 mM dithiothreitol, and
0.05% Triton X-100 for 15 min at room temperature, and
subsequently analyzed on a non-denaturating 4% acryla-
mide gel containing 45 mM Tris, 45 mM Borate and 0.1%
Triton X-100 at 450 V at 4°C. The gel was subsequently
dried and analyzed with a PhosphorImager (Molecular
Dynamics).
For the TAR conformer assay, 32P-labeled TAR RNA (200
counts/s) was denatured in 10 μl water for 1 min at 85°C
followed by snap cooling on ice. After addition of 10 μl
200 mM KCl, 100 mM Tris-HCl (pH 8.0), 5 mM MgCl2,
TAR RNA was renaturated at room temperature for 15
min. After adding 4 μl of non-denaturing loading buffer
(30% glycerol, bromophenol blue), 10 μl of the sample
was analyzed on a non-denaturating 8% acrylamide gel
(in 45 mM Tris, 45 mM Borate and 0.1% Triton X-100) at
450 V at 4°C, or on a denaturing 4% acrylamide gel (in 45
mM Tris, 45 mM Borate and 0.5 mM EDTA) at 450 V at
room temperature. The gels were dried and analyzed with
a PhosphorImager. The thermodynamic stability of TAR
RNA (nt +1 to +124) was determined with the MFold RNA
folding program (version 3.2) at the Rensselaer Polytech-
nic Institute bioinformatics web server [26,27].
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